Alkem Becomes First Indian Company To Launch Novel Antibiotic For Multiple Drug Resistance (MDR) Infections The available evidence suggests that Zidavi is a potential therapeutic option for the treatment of infections complicated by multi-drug resistant (MDR) organisms

By Teena Jose

Opinions expressed by Entrepreneur contributors are their own.

You're reading Entrepreneur India, an international franchise of Entrepreneur Media.

Pexels

Alkem (Intenza, critical care division) has announced the launch of its novel anti-infective in India under the brand name Zidavi. This is in line with company's endeavour to ensure affordability, accessibility, and availability while saving the lives of critically ill patients.

Zidavi, which is a novel combination of ceftazidime and avibactam, is recommended by the infectious disease society of America (IDSA) and the Indian council of medical research (ICMR) as a preferred treatment against OXA-48-like and Klebsiella pneumoniae carbapenemase (KPC)-producing carbapenem-resistant Enterobacteriaceae (CRE) for pyelonephritis or complicated urinary tract infections (cUTI) and in other CRE infections caused by KPC and OXA-48 producers.

"With the launch of Zidavi, our aim is to ensure that Alkem continues to remain at the forefront while partnering with clinicians for saving lives," said company spokesperson.

With the rise in infections caused by carbapenem-resistant Gram-negative organisms in India, there is a need for more effective antibiotic treatment. The available evidence suggests that Zidavi (ceftazidime-avibactam) is a potential therapeutic option for the treatment of infections complicated by multi-drug resistant (MDR) organisms. Zidavi 2.5g (ceftazidime and avibactam) for infusion is available as a sterile powdered concentrate for reconstitution. Each single-dose vial contains ceftazidime pentahydrate equivalent to 2g ceftazidime and avibactam sodium equivalent to 0.5g avibactam. It is available at an affordable price of INR 2,700/vial. Zidavi's strength lies in its indigenously developed (Active Pharmaceutical Ingredients) API, which is manufactured in the company's state-of-the-art manufacturing plant in Sikkim, the statement added, according to statement given by the company.

Alkem is a leading Indian global pharmaceutical company that manufactures and markets bio-similars and pharmaceutical formulations in India and across the globe.
Teena Jose

News Desk Reporter with Entrepreneur India

Teena is a post graduate in financial journalism. She has an avid interest in content creation, digital media and fashion.
Business Ideas

70 Small Business Ideas to Start in 2025

We put together a list of the best, most profitable small business ideas for entrepreneurs to pursue in 2025.

News and Trends

Capgemini to Acquire WNS for $3.3 Billion to Scale Agentic AI Business

The acquisition is expected to help Capgemini combine the capabilities and scale of both the companies to address the strategic opportunity driven by Agentic AI

News and Trends

Khetika Secures $18M in Series B Led by Narotam Sekhsaria Family Office and Anicut Capital

The equity round also saw continued support from existing backers, including Incofin India Progress Fund, Rajasthan Gum, and Shree Ram India Gums, as per an official statement.

News and Trends

Cyprus-based Maritime Companies Announce FDI of ₹10,000 Cr for the Indian Shipping Sector

The FDI is marked as the largest ever in the Indian shipping sector since this sector was opened to 100% FDI in the year 2005.

News and Trends

No Outsourcing, No Shortcuts: The Rise of One of the World's Most Self-Reliant Business Groups

Nowhere is this more evident than in sectors like agriculture, logistics, and manufacturing industries, where the journey from raw material to finished product spans vast networks and countless hands.

News and Trends

Centre Plans INR 2,000 Crore Incentive Scheme to Boost Domestic Drone Manufacturing

The new incentive programme is seen as an attempt to not only strengthen national security but also foster a robust domestic industry capable of serving both civilian and defence sectors.